#None #MedTech #Veeva Systems #Quality Management

A Push for Quality Management: Medtech Firms Take Action

In a significant industry shift, the 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals crucial insights into the future of medical technology. 88% of surveyed medtech companies are set to enhance their postmarket quality management within the next three years. This trend highlights a collective move towards modernization aimed at improving compliance, promoting innovation, and reducing risks throughout the product lifecycle.

Manual Processes Still Predominant

Despite these advances, a substantial portion of the industry remains rooted in legacy systems. Currently, 68% of medtech companies depend on a combination of manual processes, which include outdated paper-based methods and electronic systems that are not effectively integrated. Such reliance on antiquated practices can lead to significant delays in addressing product issues, resulting in backlogs in handling complaints and affecting overall patient safety.

Companies struggling with slow responses to safety concerns not only face compliance risks but also risk damaging their trust with consumers and tarnishing their brand reputation.

Evolving Quality Management Strategies

The findings emphasize the need for medtech companies to streamline their quality operations proactively. Several strategies are identified as vital:

• - Focus on Proactive Quality Management: The leading reasons for advancing quality include proactive quality management (mentioned by 38% of respondents) and the need for scalable processes to foster growth (identified by 26%).
• - Technology as a Catalyst: There is a consensus among industry leaders that adopting advanced technology can facilitate automation, making processes faster and more efficient. In fact, 75% of surveyed representatives believe that technology can significantly enhance timeliness and efficiency.

Underutilization of Emerging Technologies

While optimism exists regarding the potential for innovations like generative AI and robotic process automation, actual implementation has been limited. Less than 3% of the companies surveyed have integrated these technologies effectively into their workflows. However, many respondents noted that improved timeliness and efficiency through such technologies represent one of the top opportunities for quality enhancement in their operations.

Training Gaps and Future Challenges

One notable concern documented in the research is the adequacy of employee training programs. Only 19% of participants felt that their training initiatives sufficiently prepared their teams to handle postmarket quality challenges. This indicates a significant area for development, pointing to the need for enhanced training methodologies that offer real-time updates and insights into employees' responsibilities.

Vishaka Rajaram, the senior director of quality strategy at Veeva MedTech, remarked on the research findings, stating, “While initiatives are underway to simplify and connect medtech quality operations, many organizations still grapple with the limitations of outdated systems and manual processes. Aligning strategic goals with modern technology solutions can transition medtechs from reactive issue management to proactive risk prevention, ultimately leading to greater compliance and speed.”

The Road Ahead

The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed over 100 quality leaders in the medtech field. It delves into the industry’s progress, the challenges faced, and the opportunities available for improving quality management approaches.

For those keen on exploring the detailed findings and recommendations, a comprehensive version of the benchmark report is available online. As medtech companies gear up for the forthcoming years, a united focus on innovation, modernization, and training may set the stage for significant transformations in the industry.

About Veeva Systems

Veeva Systems, listed on the NYSE under the ticker VEEV, is at the forefront of providing cloud software solutions for the life sciences sector. With a commitment to innovation and customer satisfaction, Veeva serves over 1,000 clients, ranging from large biopharmaceutical corporations to emerging biotech firms. As a Public Benefit Corporation, Veeva is dedicated to balancing the needs of all stakeholders, including customers, employees, and shareholders. For further information, please visit veeva.com.